Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

(AHAC)

(AHAC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 140,891
  • Shares Outstanding, K 12,855
  • Annual Sales, $ 0 K
  • Annual Income, $ -230 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow 99.22
  • Price/Book 28.18
Trade AHAC with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.12 +20.18%
on 08/19/21
11.27 -2.75%
on 08/26/21
+0.94 (+9.38%)
since 07/26/21
3-Month
9.12 +20.18%
on 08/19/21
11.27 -2.75%
on 08/26/21
+1.04 (+10.48%)
since 05/26/21

Most Recent Stories

More News
Humacyte Announces Successful Closing of Business Combination with Alpha Healthcare Acquisition Corp.

DURHAM, N.C., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today...

AHAC : 10.96 (+7.98%)
Alpha Healthcare Acquisition Corp. Announces Shareholder Approval of Business Combination with Humacyte

NEW YORK and DURHAM, N.C., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) (“AHAC”), a special purpose acquisition company, today announced that its stockholders...

AHAC : 10.96 (+7.98%)
DMTK : 0.5854 (-4.66%)
Humacyte Highlights Robust Expanded Access Program and Patient Testimonial for Human Acellular Vessels

DURHAM, N.C., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, announced...

AHAC : 10.96 (+7.98%)
DMTK : 0.5854 (-4.66%)
Humacyte Announces Addition of Chief Commercial Officer and Integration of Commercial-Scale Manufacturing into Clinical Trial Programs

DURHAM, N.C., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today...

AHAC : 10.96 (+7.98%)
DMTK : 0.5854 (-4.66%)
Alpha Healthcare and Humacyte Announce Nominees for Election to Post-Merger Public Company Board of Directors

NEW YORK and DURHAM, N.C., Aug. 13, 2021 (GLOBE NEWSWIRE) -- Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) (“AHAC”), a special purpose acquisition company, today announced the nominees who will...

AHAC : 10.96 (+7.98%)
DMTK : 0.5854 (-4.66%)
Humacyte Announces Publication of In Vivo Data on Biovascular Pancreas Transplantation for the Treatment of Type 1 Diabetes

DURHAM, N.C., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, announced...

AHAC : 10.96 (+7.98%)
DMTK : 0.5854 (-4.66%)
Alpha Healthcare Acquisition Corp. Sets August 24, 2021, for Special Shareholder Meeting to Vote on Humacyte Business Combination

NEW YORK and DURHAM, N.C., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) (“AHAC”), a special purpose acquisition company, today announced that it has filed a...

AHAC : 10.96 (+7.98%)
DMTK : 0.5854 (-4.66%)
Humacyte Presents Potential of Functional Lung Engineering at Janelia R3 – Replace, Repair, Regenerate Planning Workshop

DURHAM, N.C., July 22, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today...

AHAC : 10.96 (+7.98%)
DMTK : 0.5854 (-4.66%)
UPDATE -- Humacyte Expands Strategic Global Partnership with Fresenius Medical Care

DURHAM, N.C., June 11, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, announces...

AHAC : 10.96 (+7.98%)
DMTK : 0.5854 (-4.66%)
Humacyte to Participate in Fireside Chat at Cowen 6th Annual FutureHealth Conference

DURHAM, N.C., June 10, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today...

AHAC : 10.96 (+7.98%)
DMTK : 0.5854 (-4.66%)

Business Summary

Alpha Healthcare Acquisition Corp. is a blank check company. It formed for the purpose of merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. Alpha Healthcare Acquisition Corp. is based in New York.

See More

Key Turning Points

3rd Resistance Point 12.53
2nd Resistance Point 11.90
1st Resistance Point 11.43
Last Price 10.96
1st Support Level 10.33
2nd Support Level 9.70
3rd Support Level 9.23

See More

52-Week High 16.96
Fibonacci 61.8% 13.97
Fibonacci 50% 13.04
Fibonacci 38.2% 12.11
Last Price 10.96
52-Week Low 9.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar